Moffitt Cancer Center, Tampa, FL
Philippe E. Spiess , Douglas A Mata , Gennady Bratslavsky , Joseph M Jacob , Andrea Necchi , Ole Gjoerup , Natalie Danziger , Douglas I. Lin , Brennan James Decker , Ethan Sokol , Richard Huang , Jeffrey S. Ross
Background: Although SCC of the penile skin (pSCC) and the male urethral surface epithelium (uSCC) arise in nearby locations and can feature similar histology, their clinical manifestations, disease course, and surgical and medical treatment options are distinct. We performed CGP on pSCC and uSCC to examine genomic profiles differences. Methods: Tissues obtained from men with clinically advanced pSCC (n = 230) and uSCC (n = 17) underwent hybrid capture-based CGP to evaluate all classes of genomic alterations (GAs). Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA and microsatellite instability (MSI) was determined on up to 114 loci. PD-L1 expression was determined by IHC (Dako 22C3). Results: The median ages were similar in both groups. pSCC exhibited a slightly higher frequency of HPV-16/18 infection (29% vs. 12%, P = .16), although the TP53 mutation frequencies were nearly identical (55% vs. 59%, NS). CDKN2A inactivation (P = .08), CCND1 amplification trending higher and TERT promoter mutations (P = .01) were more frequent in pSCC, potentially indicating prior HPV infection. GAs in NOTCH1 were exclusively identified in pSCC. Potentially actionable GAs identified in both groups included PIK3CA activating mutations (TKIs) as well as pathogenic alterations in FBXW7 and PTEN (MTOR inhibitors). Rare BRCA1 and BRCA2 inactivation (PARP inhibitors) was seen in pSCC only. High-positive PD-L1 staining was elevated in pSCC (34 vs. 14%, P = .06). Although average TMB was similar in both groups, pSCC exhibited an elevated frequency of cases with CD274 (PD-L1) amplification as well as TMB >10 mut/Mb which are on label for immune checkpoint inhibitor (ICPI) treatment. Conclusions: CGP of pSCC and uSCC identifies opportunities for both targeted and ICPI therapies. Compared to uSCC, pSCC had genomic features more similar to head and neck SCC including slightly increased cell-cycle perturbation, HPV infection, and NOTCH pathway signaling alterations. Further use of CGP in the treatment planning for pSCC and uSCC may be warranted.
Penile SCC (n = 230) | Male Urethral SCC (n = 17) | Significance | |
---|---|---|---|
Median age (range), years | 65 (24-92) | 63 (40-76) | NS |
GAs/tumor | 5.7 | 4.9 | NS |
HPV-6/11 | 3% | 0% | NS |
HPV-16/18 | 29% | 12% | NS |
BRCA1 | < 1% | 0% | NS |
BRCA2 | 3% | 0% | NS |
CCND1 amplification | 15% | 6% | NS |
CD274 amplification | 6% | 0% | NS |
CDKN2A inactivation | 47% | 24% | P = 0.08 |
CDKN2B inactivation | 9% | 0% | NS |
EGFR amplification | 14% | 12% | NS |
FBXW7 | 8% | 6% | NS |
FGFR3 | 3% | 6% | NS |
NOTCH1 | 17% | 0% | P = 0.08 |
PIK3CA | 22% | 30% | NS |
PTEN inactivation | 4% | 6% | NS |
TERT promoter mutation | 44% | 13% | P = 0.01 |
TP53 | 55% | 59% | NS |
MSI High | 1% | 0% | NS |
Median TMB | 3.8 | 3.8 | NS |
Mean TMB | 5.7 | 6.5 | NS |
TMB >10 mt/Mb | 15% | 6% | NS |
TMB >20 mt/Mb | 5% | 6% | NS |
PD-L1 Low Positive (1-49%) | 25% | 28% | NS |
PD-L1 High Positive (≥50%) | 34% | 14% | P = 0.06 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Rebecca A Sager
2022 ASCO Genitourinary Cancers Symposium
First Author: Petros Grivas
2024 ASCO Genitourinary Cancers Symposium
First Author: Stephanie Lakritz
2021 ASCO Annual Meeting
First Author: Philippe E. Spiess